Eli Lilly and Company (LLY)vsPrecigen Inc (PGEN)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
PGEN
Precigen Inc
$6.85
+2.54%
HEALTHCARE · Cap: $2.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 92841% more annual revenue ($79.67B vs $85.72M). LLY leads profitability with a 33.5% profit margin vs -184.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
PGEN
Hold40
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Strong operational efficiency at 41.2%
Revenue surging 6323.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
0.0% earnings growth
Weak financial health signals
Trading at 57.1x book value
ROE of -1145.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : PGEN
The strongest argument for PGEN centers on Operating Margin, Revenue Growth. Revenue growth of 6323.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : PGEN
The primary concerns for PGEN are EPS Growth, Piotroski F-Score, Price/Book. Debt-to-equity of 2.26 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while PGEN is a hypergrowth play — different risk/reward profiles.
PGEN carries more volatility with a beta of 1.02 — expect wider price swings.
PGEN is growing revenue faster at 6323.0% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 40/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Precigen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?